“Targeting of amyloid-beta oligomers through intrabodies: towards an innovative gene immunotherapy for Alzheimer’s disease”

External Seminars

favorite_border

calendar_month

28 Feb 11:45

“Targeting of amyloid-beta oligomers through intrabodies: towards an innovative gene immunotherapy for Alzheimer’s disease”

place Monterotondo Campus “A. Buzzati Traverso” – Via E. Ramarini, 32 Monterotondo Scalo expand_more

Speaker: Dr. Raffaella Scardigli , Phd | Institute of Translational Pharmacology, National Research Council, Rome; European Brain Research Institute (EBRI), Rome.
Role: researcher
Title: Targeting of amyloid-beta oligomers through intrabodies: towards an innovative gene immunotherapy for Alzheimer’s disease
Main field of investigation :Neurobiology
Topic: Pancreatic cancer
Researcher Host: Laura Micheli

Abstract Decrease in adult neurogenesis has been described to correlate with Alzheimer’s disease (AD) progression, and we have previously demonstrated a causal link between Amyloid-beta oligomers (AβOs) accumulation in adult neural stem cells (NSCs) and reduced SVZ neurogenesis in AD at pre-symptomatic stage. Here we investigated if AβOs targeting in the dentate gyrus of young AD mice can rescue adult hippocampal neurogenesis (AHN) and recover AD-related memory deficits. Using a disease modifying gene-therapy approach to neutralize intracellular natural-occurring AβOs in the hippocampal progenitors, we could rescue proliferation and differentiation deficits of AD-NSCs in vitro and AHN-related memory deficits in vivo. These data indicate neurogenesis as a model of AD deficits leaded by intracellular AβOs and provide AβOs gene-immunotargeting exploitable as an innovative therapeutic intervention to counteract disease onset and progression.